Harrow at Cantor healthcare conference: long view, bigger eye-care bet

On September 9, 2026, Harrow (HROW) attended the 12th Annual Cantor Fitzgerald Global Healthcare Conference to present an expanded growth strategy. The company plans to focus on a longer-term approach, aiming for five-year strategy rather than short-term prescription trends. Harrow's management expressed confidence in the current product momentum, while acknowledging challenges such as pricing fluctuations, changes in coverage, and competition.

The company reiterated its goal of achieving $250 million in quarterly revenue by calendar 2027, but emphasized that this is a goal, not formal guidance. Key growth engines identified by Harrow included VEVYE, IHEEZO, and the G-MELT program. Each of these segments has potential to expand market share.

Harrow's CEO, Mark Baum, stressed the company's focus on longer planning cycles and the transition away from weekly or monthly prescription data analysis. Baum aimed to strike a balance between managing the business on a long-term horizon and providing investors with regular financial guidance, using an "under-promising and over-delivering" approach.

The presentation highlighted progress in various areas, including dry eye, retinal anesthesia, and cataract-surgery sedation. Management noted that Harrow's next five-year plan would center on three segments: ocular surgery, retina, and ocular surface. A spring 2025 Analyst Day was expected to provide more detailed segment-level revenue and contribution information.

Harrow reiterated its financial guidance for the year and confidence in a stronger second half of 2024, with Q4 2024 expected to outperform Q3 2024. The company reaffirmed its $250 million quarterly revenue target for calendar 2027. Baum also highlighted VEVYE as a highly attractive acquisition, bought at less than 1 times trailing revenue. Other products like BYOOVIZ and OPUVIZ were described as high-margin revenue drivers.

The ophthalmology portfolio was emphasized as the core of Harrow's growth story. VEVYE, a cyclosporine product for dry eye disease, continued to gain traction, with recent coverage wins opening up new opportunities. Harrow aimed to secure number one positions in cyclosporine, anti-inflammatory, and overall prescription medication categories in dry eye.

The company already leads in these categories in certain territories, setting a template for broader expansion. VEVYE competes with products like RESTASIS, CEQUA, and Xiidra, but Harrow believes its product stands out in terms of feel, tolerability, and patient preference.

The company's retinal anesthetic, IHEEZO, was still early in its commercial life, with 2% market penetration and 98% of unit opportunities still unmet. Harrow reported record account growth and demand in the second quarter of 2024, with promising results from the DAANG study and the upcoming Quell Phase IV trial, expected in Q4 2024. Baum likened IHEEZO's potential to an iPhone 17 compared to a BlackBerry, highlighting the product's innovative advantages.